04.27.12
HP Ingredients, Bradenton, FL, has obtained U.S. patent #8,084,495 B2 for ParActin. The patent is titled “Composition of Labdane diterpenes extracted from Andrographis paniculata, useful for the treatment of autoimmune diseases, and Alzheimer Disease by activation for PPAR-Gamma receptors.” Peroxisome Proliferator Activated Receptor gamma (PPARy) is the key regulator of the immune and inflammatory response. ParActin was shown in low doses (25 to 30 mg) to stimulate immune response and at high doses (250 mg) to activate PPARy to promote healthy inflammatory response. When PPARy is activated, then NF-kappaB is inhibited. NF-kappaB, which regulates pro-inflammatory cytokines and pro-inflammatory mediators, is activated in asthma and rheumatoid synovium cells, for example. In vitro and in vivo research showed ParActin inhibited NF-kB activity and reduced significantly the DNA binding of NF-kappaB.